Rhythm Pharmaceuticals (RYTM) News Today $53.54 +1.50 (+2.88%) As of 09:40 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Rhythm Pharmaceuticals (NASDAQ:RYTM) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $70.00 price objective on shares of Rhythm Pharmaceuticals in a report on Monday.March 25 at 8:12 AM | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Given "Buy" Rating at HC WainwrightMarch 25 at 1:48 AM | americanbankingnews.com7RYTM : Analyst Expectations For Rhythm Pharmaceuticals&#...March 24 at 8:54 PM | benzinga.comConnor Clark & Lunn Investment Management Ltd. Buys New Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,089March 24 at 3:34 AM | marketbeat.comRhythm Pharmaceuticals receives orphan drug status in JapanMarch 21, 2025 | investing.comRhythm Pharmaceuticals reacquires rights to Imcivree in China for $6.3MMarch 21, 2025 | markets.businessinsider.comIs Rhythm Pharmaceuticals (RYTM) a Worst High-Risk High-Reward Growth Stock to Buy?March 21, 2025 | msn.comRhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.March 20, 2025 | globenewswire.comRhythm Pharmaceuticals gets orphan drug designation for setmelanotide in JapanMarch 20, 2025 | markets.businessinsider.comRhythm Pharmaceuticals (NASDAQ:RYTM) Given New $66.00 Price Target at Needham & Company LLCMarch 20, 2025 | americanbankingnews.comYann Mazabraud Sells 75,000 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) StockRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) EVP Yann Mazabraud sold 75,000 shares of the stock in a transaction on Friday, March 14th. The shares were sold at an average price of $51.48, for a total value of $3,861,000.00. Following the completion of the transaction, the executive vice president now directly owns 40,370 shares in the company, valued at $2,078,247.60. This trade represents a 65.01 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.March 19, 2025 | marketbeat.comRhythm Pharmaceuticals Receives Orphan-Drug Designation in Japan for Obesity TreatmentMarch 19, 2025 | marketwatch.comRhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in JapanMarch 19, 2025 | globenewswire.comNeedham & Company LLC Forecasts Strong Price Appreciation for Rhythm Pharmaceuticals (NASDAQ:RYTM) StockNeedham & Company LLC lifted their price target on Rhythm Pharmaceuticals from $64.00 to $66.00 and gave the stock a "buy" rating in a research note on Tuesday.March 19, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $24.65 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Charles Schwab Investment Management Inc. boosted its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 1.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 440,250 shaMarch 19, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research CollaborationMarch 19, 2025 | finanznachrichten.deRhythm Pharmaceuticals, Raymond A. Wood Fountain announce research collabMarch 19, 2025 | markets.businessinsider.comRhythm Pharmaceuticals price target raised to $66 from $64 at NeedhamMarch 19, 2025 | markets.businessinsider.comRhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research CollaborationMarch 18, 2025 | globenewswire.comPrimecap Management Co. CA Reduces Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Primecap Management Co. CA decreased its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 8.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,571,190 shares of the company's stock after selling 645,721March 18, 2025 | marketbeat.comStifel Nicolaus Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)March 11, 2025 | markets.businessinsider.comRhythm Pharmaceuticals' (RYTM) "Overweight" Rating Reaffirmed at Morgan StanleyMorgan Stanley reissued an "overweight" rating and issued a $72.00 target price on shares of Rhythm Pharmaceuticals in a report on Friday.March 8, 2025 | marketbeat.comRhythm Pharmaceuticals assumed with an Overweight at Morgan StanleyMarch 7, 2025 | markets.businessinsider.comHC Wainwright Issues Positive Estimate for RYTM EarningsRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Investment analysts at HC Wainwright increased their Q1 2025 earnings estimates for shares of Rhythm Pharmaceuticals in a note issued to investors on Monday, March 3rd. HC Wainwright analyst R. Selvaraju now forecasts that the company wilMarch 7, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Position Decreased by Candriam S.C.A.Candriam S.C.A. cut its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 15.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 332,392 shares of the company's stock after selling 62,985 shMarch 7, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Now Covered by Stifel NicolausStifel Nicolaus started coverage on Rhythm Pharmaceuticals in a report on Wednesday. They issued a "buy" rating and a $78.00 price target for the company.March 6, 2025 | marketbeat.comFY2026 Earnings Forecast for RYTM Issued By HC WainwrightRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Equities research analysts at HC Wainwright issued their FY2026 earnings estimates for shares of Rhythm Pharmaceuticals in a research note issued to investors on Monday, March 3rd. HC Wainwright analyst R. Selvaraju forecasts that the comMarch 6, 2025 | marketbeat.comRhythm Pharmaceuticals resumed with a Buy at StifelMarch 6, 2025 | markets.businessinsider.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of "Moderate Buy" by BrokeragesRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and ten have issued a buy ratinMarch 4, 2025 | marketbeat.comY Intercept Hong Kong Ltd Invests $328,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Y Intercept Hong Kong Ltd acquired a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,866 shares of the company's stock, valueMarch 4, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, HC Wainwright Analyst SaysHC Wainwright increased their target price on shares of Rhythm Pharmaceuticals from $69.00 to $70.00 and gave the stock a "buy" rating in a report on Monday.March 3, 2025 | marketbeat.comRhythm Pharmaceuticals price target raised to $70 from $69 at H.C. WainwrightMarch 3, 2025 | markets.businessinsider.comRhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $81.00Canaccord Genuity Group lifted their target price on shares of Rhythm Pharmaceuticals from $80.00 to $81.00 and gave the company a "buy" rating in a report on Thursday.February 28, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Earns Buy Rating from Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $64.00 price target on shares of Rhythm Pharmaceuticals in a research report on Thursday.February 28, 2025 | marketbeat.comRhythm Pharmaceuticals price target raised to $81 from $80 at CanaccordFebruary 28, 2025 | markets.businessinsider.comRhythm Pharmaceuticals price target raised to $81 from $75 at Citizens JMPFebruary 28, 2025 | markets.businessinsider.comRhythm Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS In LineFebruary 27, 2025 | uk.finance.yahoo.comRhythm Pharmaceuticals Inc (RYTM) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...February 27, 2025 | finance.yahoo.comRhythm Pharmaceuticals, Inc. (RYTM) Q4 2024 Earnings Call TranscriptFebruary 26, 2025 | seekingalpha.comRhythm Pharmaceuticals, Inc. 2024 Q4 - Results - Earnings Call PresentationFebruary 26, 2025 | seekingalpha.comRhythm Pharmaceuticals (NASDAQ:RYTM) Issues Earnings ResultsRhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%.February 26, 2025 | marketbeat.comRhythm Pharmaceuticals announces partnership with TrisperaFebruary 26, 2025 | markets.businessinsider.comRhythm Pharmaceuticals completes enrollment in Phase 2 trial of bivamelagonFebruary 26, 2025 | markets.businessinsider.comRhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business UpdateFebruary 26, 2025 | globenewswire.comRhythm Pharmaceuticals Q4 2024 Earnings PreviewFebruary 25, 2025 | msn.comState of New Jersey Common Pension Fund D Purchases Shares of 35,004 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)State of New Jersey Common Pension Fund D acquired a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquFebruary 25, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Christopher Paul German Sells 635 SharesRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) CAO Christopher Paul German sold 635 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total transaction of $36,334.70. Following the completion of the transaction, the chief accounting officer now directly owns 2,070 shares of the company's stock, valued at approximately $118,445.40. This represents a 23.48 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.February 20, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells $70,266.16 in StockRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) insider Joseph Shulman sold 1,228 shares of the company's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total value of $70,266.16. Following the completion of the transaction, the insider now directly owns 8,509 shares of the company's stock, valued at $486,884.98. This represents a 12.61 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.February 20, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Jennifer Kayden Lee Sells 2,035 SharesRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) EVP Jennifer Kayden Lee sold 2,035 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $57.22, for a total value of $116,442.70. Following the completion of the transaction, the executive vice president now owns 5,858 shares in the company, valued at $335,194.76. The trade was a 25.78 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.February 20, 2025 | marketbeat.comHunter C. Smith Sells 2,215 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) StockRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) CFO Hunter C. Smith sold 2,215 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $57.22, for a total value of $126,742.30. Following the completion of the sale, the chief financial officer now directly owns 109,929 shares in the company, valued at $6,290,137.38. This represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.February 20, 2025 | marketbeat.com Remove Ads Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address RYTM Media Mentions By Week RYTM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RYTM News Sentiment▼0.420.63▲Average Medical News Sentiment RYTM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RYTM Articles This Week▼237▲RYTM Articles Average Week Remove Ads Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Moderna News Today Genmab A/S News Today Dr. Reddy's Laboratories News Today Viatris News Today Ascendis Pharma A/S News Today Vaxcyte News Today Qiagen News Today Roivant Sciences News Today Sarepta Therapeutics News Today Revolution Medicines News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RYTM) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
